Skip to main content

Atezolizumab (atezo) as first-line (1L) therapy in patients (pts) with cisplatin (cis)-ineligible locally advanced or metastatic urothelial cancer (mUC): efficacy by PD-L1 status over time from IMvigor210 Cohort 1

Durán
Ignacio
Medical Oncology
Hospital Universitario Marques de Valdecilla
Santander
Cantabria
Spain
Show all authors
Dreicer
Robert
Division of Hematology/Oncology
University of Virginia
Charlottesville
VA
United States
Loriot
Yohann
Oncology
Gustave Roussy
Villejuif
France
Gracia
José Luis Pérez
Medical Oncology
Clínica Universidad de Navarra
Pamplona
Spain
Hoffman-Censits
Jean H.
Oncology
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
Baltimore
MD
United States
Petrylak
Daniel P.
Medical Oncology
Yale Cancer Center
New Haven
CT
United States
van der Heijden
Michiel S
Molecular Carcinogenesis
Netherlands Cancer Institute
Amsterdam
the Netherlands
Ding
Beiying
Oncology
Genentech, Inc.
South San Francisco
CA
United States
Shen
Xiaodong
Oncology
Genentech, Inc.
South San Francisco
CA
United States
Antic
Vladan
Oncology
F. Hoffmann-La Roche, Ltd.
Basel
Switzerland
Rosenberg
Jonathan E.
Medical Oncology
Memorial Sloan Kettering Cancer Center
New York
NY
United States
Balar
Arjun V.
Perlmutter Cancer Center
NYU Langone Health
New York
NY
United States

Tabs

Speciality: 
Oncology (medical)
Keywords: 
PD-L1, atezolizumab, metastatic urothelial cancer (mUC)